Lupin has entered into the prescription dermatology segment in Brazil with the launch of Fillerina and Recrexina under the Lupin High-End Skin Science umbrella. Valued at $28 billion, Brazil is the world's 6th largest pharmaceutical market, driven by growing public health expenditure and increasing household income. The dermatology segment in Brazil, worth $1.5 billion, and growing at 10% (CAGR) is one of the fastest growing segments in the country.
As part of the launch, Lupin has also launched a 360-degree communications campaign, focused on healthcare professionals, pharmacy chains and regional and national medical associations in Brazil.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1622.45 |
| Dr. Reddys Lab | 1316.50 |
| Cipla | 1288.00 |
| Zydus Lifesciences | 932.20 |
| Lupin | 2281.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: